Cargando…

BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer

Lung cancer is the leading cause of cancer deaths worldwide. Immunotherapies (IT) have been rapidly approved for lung cancer treatment after the spectacular results in melanoma. Responses to the currently used checkpoint inhibitors are strikingly good especially in metastatic diseases. However, dura...

Descripción completa

Detalles Bibliográficos
Autores principales: Demerlé, Clemence, Gorvel, Laurent, Olive, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438526/
https://www.ncbi.nlm.nih.gov/pubmed/34532285
http://dx.doi.org/10.3389/fonc.2021.682007
_version_ 1783752364453265408
author Demerlé, Clemence
Gorvel, Laurent
Olive, Daniel
author_facet Demerlé, Clemence
Gorvel, Laurent
Olive, Daniel
author_sort Demerlé, Clemence
collection PubMed
description Lung cancer is the leading cause of cancer deaths worldwide. Immunotherapies (IT) have been rapidly approved for lung cancer treatment after the spectacular results in melanoma. Responses to the currently used checkpoint inhibitors are strikingly good especially in metastatic diseases. However, durable responses are observed in only 25% of cases. Consequently, there is an urgent need for new immunotherapy targets. Among the multiple checkpoints involved in the tumor immune escape, the BTLA-HVEM couple appears to be a promising target. BTLA (B- and T- Lymphocyte Attenuator) is a co-inhibitory receptor mainly expressed by B and T cells, repressing the activation signal transduction. BTLA shares similarities with other immune checkpoints such as PD-1 and CTLA-4 which are the targets of the currently used immunotherapies. Furthermore, BTLA expression points out terminally exhausted and dysfunctional lymphocytes, and correlates with lung cancer progression. The ligand of BTLA is HVEM (Herpes Virus Entry Mediator) which belongs to the TNF receptor family. Often described as a molecular switch, HVEM is constitutively expressed by many cells, including cells from tumor and healthy tissues. In addition, HVEM seems to be involved in tumor immuno-evasion, especially in lung tumors lacking PD-L1 expression. Here, we propose to review the role of BTLA-HVEM in immuno-escape in order to highlight its potential for designing new immunotherapies.
format Online
Article
Text
id pubmed-8438526
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84385262021-09-15 BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer Demerlé, Clemence Gorvel, Laurent Olive, Daniel Front Oncol Oncology Lung cancer is the leading cause of cancer deaths worldwide. Immunotherapies (IT) have been rapidly approved for lung cancer treatment after the spectacular results in melanoma. Responses to the currently used checkpoint inhibitors are strikingly good especially in metastatic diseases. However, durable responses are observed in only 25% of cases. Consequently, there is an urgent need for new immunotherapy targets. Among the multiple checkpoints involved in the tumor immune escape, the BTLA-HVEM couple appears to be a promising target. BTLA (B- and T- Lymphocyte Attenuator) is a co-inhibitory receptor mainly expressed by B and T cells, repressing the activation signal transduction. BTLA shares similarities with other immune checkpoints such as PD-1 and CTLA-4 which are the targets of the currently used immunotherapies. Furthermore, BTLA expression points out terminally exhausted and dysfunctional lymphocytes, and correlates with lung cancer progression. The ligand of BTLA is HVEM (Herpes Virus Entry Mediator) which belongs to the TNF receptor family. Often described as a molecular switch, HVEM is constitutively expressed by many cells, including cells from tumor and healthy tissues. In addition, HVEM seems to be involved in tumor immuno-evasion, especially in lung tumors lacking PD-L1 expression. Here, we propose to review the role of BTLA-HVEM in immuno-escape in order to highlight its potential for designing new immunotherapies. Frontiers Media S.A. 2021-08-31 /pmc/articles/PMC8438526/ /pubmed/34532285 http://dx.doi.org/10.3389/fonc.2021.682007 Text en Copyright © 2021 Demerlé, Gorvel and Olive https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Demerlé, Clemence
Gorvel, Laurent
Olive, Daniel
BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer
title BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer
title_full BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer
title_fullStr BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer
title_full_unstemmed BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer
title_short BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer
title_sort btla-hvem couple in health and diseases: insights for immunotherapy in lung cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8438526/
https://www.ncbi.nlm.nih.gov/pubmed/34532285
http://dx.doi.org/10.3389/fonc.2021.682007
work_keys_str_mv AT demerleclemence btlahvemcoupleinhealthanddiseasesinsightsforimmunotherapyinlungcancer
AT gorvellaurent btlahvemcoupleinhealthanddiseasesinsightsforimmunotherapyinlungcancer
AT olivedaniel btlahvemcoupleinhealthanddiseasesinsightsforimmunotherapyinlungcancer